Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.

Literature DB >> 26402128

Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.

Steven P Rowe¹, Michael A Gorin, Hans J Hammers, Martin G Pomper, Mohammad E Allaf, Mehrbod Som Javadi.

Abstract

Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2016 PMID： 26402128 PMCID： PMC4834697 DOI： 10.1097/RLU.0000000000000995

Source DB: PubMed Journal: Clin Nucl Med ISSN： 0363-9762 Impact factor: 7.794

8 in total

1. ⁶⁸Ga-PSMA imaging of metastatic breast cancer.

Authors: Mike Sathekge; Moshe Modiselle; Mariza Vorster; Neo Mokgoro; Nozipho Nyakale; Brenda Mokaleng; Thomas Ebenhan
Journal: Eur J Nucl Med Mol Imaging Date: 2015-05-01 Impact factor: 9.236

2. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Authors: Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal: J Nucl Med Date: 2015-06-11 Impact factor: 10.057

3. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors: Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-23 Impact factor: 9.236

4. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors: Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488

5. Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Authors: S S Chang; D S O'Keefe; D J Bacich; V E Reuter; W D Heston; P B Gaudin
Journal: Clin Cancer Res Date: 1999-10 Impact factor: 12.531

6. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.

Authors: Matthias Eiber; Tobias Maurer; Michael Souvatzoglou; Ambros J Beer; Alexander Ruffani; Bernhard Haller; Frank-Philipp Graner; Hubert Kübler; Uwe Haberkorn; Michael Eisenhut; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger
Journal: J Nucl Med Date: 2015-03-19 Impact factor: 10.057

7. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors: Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal: Urology Date: 2007-08 Impact factor: 2.649

8. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Authors: Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper
Journal: J Nucl Med Date: 2012-12 Impact factor: 10.057

8 in total

20 in total

1. Renal cell carcinoma: the search for a reliable biomarker.

Authors: Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal: Transl Cancer Res Date: 2017-06 Impact factor: 1.241

2. Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Authors: Ben T Copeland; Hassan Shallal; Chentian Shen; Kenneth J Pienta; Catherine A Foss; Martin G Pomper
Journal: Mol Imaging Biol Date: 2019-12 Impact factor: 3.488

3. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [¹⁸F]DCFPyL PET/CT.

Authors: Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal: Mol Imaging Biol Date: 2019-06 Impact factor: 3.488

Review 4. Current use of PSMA-PET in prostate cancer management.

Authors: Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal: Nat Rev Urol Date: 2016-02-23 Impact factor: 14.432

5. Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors: Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal: J Nucl Med Date: 2017-09-08 Impact factor: 10.057

6. [⁶⁸Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors: Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal: Am J Nucl Med Mol Imaging Date: 2020-12-15

Review 7. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Authors: Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone
Journal: Curr Urol Rep Date: 2019-10-11 Impact factor: 3.092

Review 8. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Authors: Thomas Ahn; Matthew J Roberts; Aous Abduljabar; Andre Joshi; Marlon Perera; Handoo Rhee; Simon Wood; Ian Vela
Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488

Review 9. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.

Authors: Steven P Rowe; Alexander Drzezga; Bernd Neumaier; Markus Dietlein; Michael A Gorin; Michael R Zalutsky; Martin G Pomper
Journal: J Nucl Med Date: 2016-10 Impact factor: 10.057

10. Diagnostic potential of PET/CT using a ⁶⁸Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.

Authors: Lino M Sawicki; Christian Buchbender; Johannes Boos; Markus Giessing; Johannes Ermert; Christina Antke; Gerald Antoch; Hubertus Hautzel
Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-21 Impact factor: 9.236